buy excel 2010 best buy graphisoft archicad 12 buy cost of office 2008 buy adobe indesign cs4 for mac discount abbyy finereader buy microsoft office 2003 cheap best buy corel videostudio buy microsoft office access 2007 uk buy acronis true image home 2011 buy win xp pro uk buy windows 7 enterprise product key coreldraw graphics suite x7 download buy excel for mac discount microsoft word 2008 buy 2007 microsoft word product key online best price photoshop cs6 extended buy adobe acrobat standard buy windows 7 deals purchase adobe acrobat 9 standard buy adobe audition for mac purchase after effects cs4 price of microsoft office 2007 enterprise best price quicken 2010 starter edition buy rosetta stone mac cost of screenflow buy corel paint shop pro x2 ultimate cost of autocad architecture price of coreldraw graphics suite x7 cheap windows xp professional software buy price of adobe elements

New biomarker technique could provide early detection for cancer

Wed, May 19, 2010

Oral Cancer News

Author: press release provided by University of Connecticut

Modern genetic testing can predict your risk of contracting particular diseases based on predispositions discovered in your DNA. But what if similar biotechnology could tell you that you’ve got a disease before you notice any symptoms? What if it could even tell you, before any signs of a tumor, that you have cancer?

Jim Rusling, professor of chemistry at UConn and professor of cell biology at the UConn Health Center, ponders these questions on a daily basis. Since 2006, he and colleagues at the University and the National Institutes of Health (NIH) have been developing techniques to detect biomarker proteins – the physiological traits that indicate that a person has a specific disease – for prostate and oral cancer. Because these biomarkers are often present in the blood in a disease’s early stages, they can be used for early detection and prevention.

“DNA predicts which proteins can be made, but it can’t predict which proteins are actively expressed,” Rusling says. “It only assesses the risk of a disease. There’s a big push now to measure proteins as biomarkers.”

In a recent publication in the journal Analytical Chemistry, Rusling and his colleagues describe a system they developed to detect with record sensitivity the bloodstream levels of a protein associated with several types of oral cancer, including head and neck squamous cell carcinomas. The project was funded by a $1.5 million grant from the National Institute of Environmental Health Sciences at NIH.

The protein, called interleukin-6 or IL-6, is normally present in very low levels in the bloodstream – so low that previous biomarker sensors might not be able to detect it. This and other biomarkers are signaling molecules, which can instruct cells that have become cancerous to grow faster. Their levels can increase even before tumors begin to form, enabling early detection that might head off the formation of cancerous growths.

Print Friendly
Be Sociable, Share!
, , , , , ,

Leave a Reply

You must be logged in to post a comment.